<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681131</url>
  </required_header>
  <id_info>
    <org_study_id>BA3011-002</org_study_id>
    <nct_id>NCT04681131</nct_id>
  </id_info>
  <brief_title>CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC</brief_title>
  <official_title>A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioAtla, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioAtla, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label, Phase 2 study designed to evaluate the safety,&#xD;
      tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active&#xD;
      biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC), alone and in combination&#xD;
      with PD-1 inhibitor in patients with metastatic non-small cell lung cancer (NSCLC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Objective Response Rate (ORR) per RECIST v1.1</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Proportion of patients who achieve a confirmed CR or PR according to RECIST v1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events or Serious Adverse Events as assessed by CTCAE v4.03/v5</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Measured by frequency and severity of adverse events as assessed by CTCAE v4.03/v5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from the first documented OR until the first documented disease progression or death (due to any cause), whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from the first dose of IP until the first documentation of disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (OR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>All post-baseline disease assessments that occur prior to the initiation of subsequent anticancer therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Proportion of patients with a best overall response of confirmed CR, confirmed PR, or stable disease (SD) ≥ 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from the first dose of investigational product until the first documentation of OR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from the first dose of BA3021 treatment until death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Non-Small-Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>CAB-AXL-ADC (BA3011)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAB-AXL-ADC (BA3011) alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAB-AXL-ADC (BA3011)+PD-1 inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAB-AXL-ADC (BA3011) with PD-1 inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAB-AXL-ADC</intervention_name>
    <description>Conditionally active biologic anti-AXL antibody drug conjugate</description>
    <arm_group_label>CAB-AXL-ADC (BA3011)</arm_group_label>
    <arm_group_label>CAB-AXL-ADC (BA3011)+PD-1 inhibitor</arm_group_label>
    <other_name>BA3011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PD-1 inhibitor</intervention_name>
    <description>PD-1 inhibitor</description>
    <arm_group_label>CAB-AXL-ADC (BA3011)+PD-1 inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have measurable disease.&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Adequate liver function&#xD;
&#xD;
          -  Adequate hematological function&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Life expectancy of at least three months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients must not have clinically significant cardiac disease.&#xD;
&#xD;
          -  Patients must not have known non-controlled CNS metastasis.&#xD;
&#xD;
          -  Patients must not have had prior therapy with a conjugated or unconjugated auristatin&#xD;
             derivative/vinca-binding site targeting payload.&#xD;
&#xD;
          -  Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as&#xD;
             well as known or suspected allergy or intolerance to any agent given during this&#xD;
             study.&#xD;
&#xD;
          -  Patients must not have had major surgery within 4 weeks before first BA3011&#xD;
&#xD;
          -  Patients must not have known human immunodeficiency virus (HIV) infection, active&#xD;
             hepatitis B and/or hepatitis C.&#xD;
&#xD;
          -  Patients must not be women who are pregnant or breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ji Hwan Lee</last_name>
    <phone>858-286-7702</phone>
    <email>jlee@bioatla.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hazel Buncab</last_name>
    <phone>858-263-1598</phone>
    <email>hbuncab@bioatla.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Plattner</last_name>
      <phone>720-848-0696</phone>
      <email>nathan.plattner@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>David Camidge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Fleming Island</city>
        <state>Florida</state>
        <zip>32003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila Gagne</last_name>
      <phone>904-269-6526</phone>
      <email>sgagne@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Augusto Villegas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>239-274-9930</phone>
    </contact>
    <investigator>
      <last_name>Ivor Percent</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukas Escobar</last_name>
      <phone>727-216-1143</phone>
      <email>lukas.escobar@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Vipul Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>De'Dra Kelly</last_name>
      <phone>561-366-4100</phone>
      <email>dkelly@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Eric Harris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology/Oncology Clinic</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Alumbaugh</last_name>
      <phone>225-761-3951</phone>
      <email>aimee.alumbaugh@aoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Castine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karishma Gupta</last_name>
      <phone>702-862-1114</phone>
      <email>Karishma.Gupta@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Ramalingam Ratnasabapathy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OptumCare Cancer Care</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Littlefield</last_name>
      <phone>702-384-0013</phone>
      <email>v.littlefield@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>John Ellerton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FirstHealth Outpatient Cancer Center</name>
      <address>
        <city>Pinehurst</city>
        <state>North Carolina</state>
        <zip>28374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Williams</last_name>
      <phone>910-715-1922</phone>
      <email>jcwilliams@firsthealth.org</email>
    </contact>
    <investigator>
      <last_name>Charles Kuzma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Research Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deshpal Bali</last_name>
      <phone>330-492-3345</phone>
      <email>dbali@gabrailcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Mayr</last_name>
      <phone>412-623-4029</phone>
      <email>mayrdc@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Liza Villaruz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Scott Maheu</last_name>
      <phone>615-341-7875</phone>
      <email>ashley.scott4@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Melissa Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrell Martinez</last_name>
      <phone>214-658-1946</phone>
      <email>tmartinez@marycrowley.org</email>
    </contact>
    <investigator>
      <last_name>James Strauss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

